EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome

Demi J Trueba-Timmermans iD, Lionne N Grootjen, Alicia F Juriaans, Eva F Mahabier, Gerthe F Kerkhof, Edmond H H M Rings, Anita C S Hokken-Koelega iD

European Journal of Endocrinology · 2023

DOI: 10.1093/ejendo/lvad084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Demi J Trueba-Timmermans und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Reference Center for Prader-Willi Syndrome, 3016 AH Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Human Growth Hormone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Most patients with Prader–Willi syndrome (PWS) have mild to moderate cognitive impairment. Growth hormone (GH) treatment has positive short- and long-term effects on cognition in children with PWS. Few studies, however, have investigated the effects of GH on cognitive functioning in adults with PWS.

Objective

To investigate the effects of 3 years of GH treatment on cognitive functioning and behavior in young adults with PWS who were treated with GH during childhood.

Design

Open-label, prospective study.

Setting

Dutch PWS Reference Center.

Methods

Patients were treated with 0.33 mg GH/m²/day (∼0.012 mg/kg/day; 33% of childhood dose). Cognitive functioning was measured by Wechsler Adult Intelligence (WAIS) tests. Behavior was studied by a developmental behavior checklist—parents/caregivers (DBC-P).

Results

Forty-six young adults with PWS with a median age of 19 (IQR 17-21) years were investigated. Estimated mean (95% CI) total, verbal, and performance IQ remained stable during 3 years of GH-treatment. Total IQ being 66 (63-69) at the start and 67 (64-71) after 3 years (P = .30); Verbal IQ being 65 (62-68) and 66 (62-70), respectively (P = .31) and performance IQ being 67 (63-70) and 67 (63-72) resp. (P = .42). Estimated mean Total DBC score did not significantly change during 3 years of GH-treatment, being 36.3 at start and 36.5 after 3 years (P = .94) (P50).

Conclusions

Three years of GH-treatment in young adults with PWS with 33% of the pediatric dose, maintains total, verbal, and performance IQ. The emotional and behavioral disturbances remained stable and were similar compared to peers with other intellectual disabilities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prader-Willi SyndromeHuman Growth HormoneHumansChildYoung AdultAdolescentAdultGrowth HormoneProspective StudiesCognition

Stichwörter der Autor:innen

Prader–Willi syndromeadultsbehaviorcognitive functioninggrowth hormone

Substanzen

Growth HormoneHuman Growth Hormone

Autor:innen und Institutionen

  • Dutch Reference Center for Prader-Willi Syndrome, 3016 AH Rotterdam, The Netherlands.
  • Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands.
  • Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
  • Department of Pediatrics, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
  • Department of Pediatrics, Leiden University Medical Center-Willem-Alexander Children's Hospital, 2333 ZA Leiden, The Netherlands.

ORCID-Profile: Demi J Trueba-Timmermans, Anita C S Hokken-Koelega

Förderung

  • Pfizer

Zitieren

APA

Trueba-Timmermans, D. J., Grootjen, L. N., Juriaans, A. F., Mahabier, E. F., Kerkhof, G. F., Rings, E. H. H. M., & Hokken-Koelega, A. C. S. (2023). Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad084

Vancouver

Trueba-Timmermans DJ, Grootjen LN, Juriaans AF, Mahabier EF, Kerkhof GF, Rings EHHM, et al. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad084

BibTeX
@article{TruebaTimmermans2023,
  author = {Trueba-Timmermans, Demi J and Grootjen, Lionne N and Juriaans, Alicia F and Mahabier, Eva F and Kerkhof, Gerthe F and Rings, Edmond H H M and Hokken-Koelega, Anita C S},
  title = {Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome},
  journal = {European Journal of Endocrinology},
  year = {2023},
  doi = {10.1093/ejendo/lvad084}
}
Kostenlos starten →